கீமோதெரபி: திறந்த அணுகல்
திறந்த அணுகல்

சுருக்கம்

IEV versus ESHAP for Treatment of the Patients with Relapsed/Refractory Hodgkin and Non-Hodgkin's Lymphoma in Iran: A Cost-Effectiveness Analysis

Mostafa Habibian and Mehdi dehghani

Background: The aim of this study was to perform cost-effectiveness Analysis of IEV versus ESHAP chemotherapy regimen in patients with Lymphoma in Iran. Materials and Methods: Our study used a cross-sectional design done as a double-blind study of 65 patients suffering from relapsed/refractory Hodgkin and non-Hodgkin's Lymphoma in Amir Oncology Hospital in Shiraz, in the south of Iran. The costs were included medical and non-medical direct costs and indirect costs. Effectiveness was reported in patient records and it was categorized into complete response, partial response and non- response Results: The direct cost in IEV and ESHAP regimens 32159.87 and 69,143.72 respectively. In IEV arm, 53% of the patients with Hodgkin Lymphoma achieved complete response (CRs) and 35% a partial response (PRs). The overall response rate (CRs & PRs) was 88.2%. But in ESHAP arm, the overall response rate was 69.2%, 43.3% of patients achieved a complete response and 27% a partial response. Conclusions: The results showed that IEV versus ESHAP was dominant in the treatment of patients with lymphoma. Also, ICER was -$109749.23 (using IEV saves $109749.23 per each additional effectiveness).